American Association for Cancer Research
15357163mct130255-sup-fig_leg.pdf (91.63 kB)

Supplementary Figure Legends from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Download (91.63 kB)
journal contribution
posted on 2023-04-03, 14:09 authored by Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum, Sharlene Adams, Sergio Iadevaia, Jian Tang, Victoria Rimkunas, Lihui Xu, Neeraj Kohli, Rachel Rennard, Maja Razlog, Yang Jiao, Brian D. Harms, Kenneth J. Olivier, Birgit Schoeberl, Ulrik B. Nielsen, Alexey A. Lugovskoy

PDF - 91K, Supplementary Figure Legends.



Although inhibition of the insulin-like growth factor (IGF) signaling pathway was expected to eliminate a key resistance mechanism for EGF receptor (EGFR)-driven cancers, the effectiveness of IGF-I receptor (IGF-IR) inhibitors in clinical trials has been limited. A multiplicity of survival mechanisms are available to cancer cells. Both IGF-IR and the ErbB3 receptor activate the PI3K/AKT/mTOR axis, but ErbB3 has only recently been pursued as a therapeutic target. We show that coactivation of the ErbB3 pathway is prevalent in a majority of cell lines responsive to IGF ligands and antagonizes IGF-IR–mediated growth inhibition. Blockade of the redundant IGF-IR and ErbB3 survival pathways and downstream resistance mechanisms was achieved with MM-141, a tetravalent bispecific antibody antagonist of IGF-IR and ErbB3. MM-141 potency was superior to monospecific and combination antibody therapies and was insensitive to variation in the ratio of IGF-IR and ErbB3 receptors. MM-141 enhanced the biologic impact of receptor inhibition in vivo as a monotherapy and in combination with the mTOR inhibitor everolimus, gemcitabine, or docetaxel, through blockade of IGF-IR and ErbB3 signaling and prevention of PI3K/AKT/mTOR network adaptation. Mol Cancer Ther; 13(2); 410–25. ©2013 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager